Bitcoin traded around $80,693, down 1.25% as investors await the US Federal Reserve's rate decision on October 28 and a major $11.1 billion bitcoin options expiry on October 30. The market largely expects no rate hike this week, shifting the probability of an increase to December. These events influence bitcoin's price through changes in safe asset yields, the US dollar strength, and derivatives financing costs. Key price levels to watch are $81,939 on the upside and $78,000 on the downside, with leveraged positions needing careful risk management ahead of these dates. The options expiry is unlikely to move the market significantly as most contracts are out of the money.
Bitcoin price outlook is in focus as the US Federal Reserve decision and a large options expiry approach. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Oct 24, 2026 21:01 WIB: out of 50 major cryptocurrencies, 5 rose and 43 fell today. Notable movers include ATOM at Rp30.030 with a 1-day change of -5.88%, AAVE at Rp2.510.899 down 5.64%, and SNX at Rp3.647 down 5.52%.
The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...
XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...
XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...
Genmab and Incyte announced a Phase 1/2 clinical trial to test a combination of petosemtamab, INCB161734, and standard chemotherapy as a first-line treatment for metastatic colorectal cancer with the KRAS G12D mutation. This mutation is common and li...
Nanobiotix announced positive Phase 1 trial results for JNJ-1900 (NBTXR3), used with radiotherapy and immune checkpoint inhibitors, in 24 heavily pretreated advanced melanoma patients resistant to anti-PD-1 therapies. The treatment showed a 41.7% obj...
